{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:57:50Z","timestamp":1790985470618,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22S11903900"],"award-info":[{"award-number":["22S11903900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117063","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:18:59Z","timestamp":1790291939000},"page":"117063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)"],"prefix":"10.1016","volume":"248","author":[{"given":"Yiqun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3831-6583","authenticated-orcid":false,"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117063_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ejca.2026.117063_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153697","article-title":"Triple negative breast cancer: a mountain yet to be scaled despite the triumphs","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.117063_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.25122\/jml-2021-0108","article-title":"Triple-negative breast cancer: current treatment strategies and factors of negative prognosis","volume":"15","author":"Baranova","year":"2022","journal-title":"J Med Life"},{"key":"10.1016\/j.ejca.2026.117063_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18091352","article-title":"PD-L1-guided chemo-immunotherapy in advanced triple-negative breast cancer: a meta-analysis of survival benefits and toxicity profiles","volume":"18","author":"Nan","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.117063_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1515\/med-2020-0138","article-title":"A review of current progress in triple-negative breast cancer therapy","volume":"15","author":"Shen","year":"2020","journal-title":"Open Med (Wars)"},{"key":"10.1016\/j.ejca.2026.117063_bib7","article-title":"Immunotherapy for triple-negative breast cancer: combination strategies to improve outcome","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.117063_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117063_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117063_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134579","article-title":"Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives","volume":"21","author":"Cocco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.117063_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26062773","article-title":"Role of PARP inhibitors: a new hope for breast cancer therapy","volume":"26","author":"De","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.117063_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","article-title":"Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy","volume":"12","author":"Lim","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117929","article-title":"Novel targeted therapies and immunological strategies for breast cancer treatment","volume":"250","author":"Mussa","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2026.117063_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.117063_bib15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2026.117063_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejca.2026.117063_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejca.2026.117063_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117063_bib19","article-title":"Datopotamab deruxtecan: first approval","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2026.117063_bib20","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.117063_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e13131","article-title":"Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Du","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100165","article-title":"Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2-targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors","volume":"53","author":"Cheng","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2026.117063_bib23","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117063_bib24","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib25","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.117063_bib27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117063_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","article-title":"Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:48:05Z","timestamp":1790984885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0959804926008452"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117063","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117063"}}